MHIG Milliman Healthcare Inflation Guard ETF
Quote as of Oct 09, 2026 13:46 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 19.92 | Day Range | 19.92 – 19.99 |
| 52-Week Range | 19.64 – 20.59 | Volume | 30 |
| Avg Volume | 135 | AUM | $996.6K (Oct 10, 2026) |
| Expense Ratio | 0.55% | Yield (TTM) | — |
| NAV | 19.93 | Premium/Discount | -0.07% indicative |
| Inception | Apr 21, 2026 | Holdings | 87 |
| Issuer | Milliman | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 600825103 | ISIN | US6008251034 |
| Management | Not stated in source data | ||
About this ETF
The Milliman Healthcare Inflation Guard ETF (MHIG) aims to counteract the rising expenditures in healthcare, distinct from general economic inflation, by utilizing proprietary actuarial data and sophisticated quantitative modeling. Its analytical foundation relies on Milliman's extensive collection of genuine healthcare claims, encompassing roughly 35 million insured individuals, to project future healthcare inflation through observed trends in medical and pharmacy costs. The fund's investments include a mix of equities and fixed-income securities spanning the entire healthcare supply chain, supplemented by instruments designed to hedge against inflation such as commodities, Treasury Inflation-Protected Securities (TIPS), and U.S. Treasury bonds. A quantitative model typically directs the fund's monthly rebalancing to adapt to changes in U.S. healthcare cost inflation. This strategy dynamically alters its asset allocation, increasing its focus on equities and commodities when inflation is elevated, and shifting towards debt instruments as inflationary pressures subside. The portfolio may also include various derivative instruments like swaps, options, and futures, in addition to exchange-traded funds (ETFs).
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -0.30% | +0.81% | — | — | — | — | — | — | -0.55% |
| Total return | -0.30% | +0.81% | — | — | — | — | — | — | -0.55% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.55% | Annual cost of a $10,000 investment | $55.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 88 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | BondBloxx Bloomberg Five Year Target Duration… | XFIV | 32.14% | 6.85K | $320.0K |
| 2 | BondBloxx Bloomberg Six Month Target Duration… | XHLF | 18.31% | 3.64K | $182.3K |
| 3 | United States Treasury Bill 11/19/2026 | — | 16.54% | 165.50K | $164.8K |
| 4 | Eli Lilly & Co | LLY | 6.22% | 53 | $62.0K |
| 5 | State Street SPDR S&P 500 ETF Trust | SPY | 5.28% | 68 | $52.6K |
| 6 | AbbVie Inc | ABBV | 2.33% | 85 | $23.2K |
| 7 | Johnson & Johnson | JNJ | 1.93% | 75 | $19.2K |
| 8 | Amgen Inc | AMGN | 1.43% | 35 | $14.3K |
| 9 | Thermo Fisher Scientific Inc | TMO | 1.24% | 19 | $12.4K |
| 10 | Gilead Sciences Inc | GILD | 1.17% | 79 | $11.6K |
| 11 | Intuitive Surgical Inc | ISRG | 0.79% | 19 | $7.9K |
| 12 | 4GLD US 11/19/26 C372.46 FLX | — | 0.76% | 5 | $7.6K |
| 13 | Danaher Corp | DHR | 0.70% | 32 | $7.0K |
| 14 | Abbott Laboratories | ABT | 0.68% | 69 | $6.8K |
| 15 | Pfizer Inc | PFE | 0.66% | 238 | $6.6K |
| 16 | Stryker Corp | SYK | 0.58% | 21 | $5.8K |
| 17 | Bristol-Myers Squibb Co | BMY | 0.56% | 94 | $5.6K |
| 18 | Merck & Co Inc | MRK | 0.44% | 31 | $4.4K |
| 19 | McKesson Corp | MCK | 0.37% | 4 | $3.7K |
| 20 | Natera Inc | NTRA | 0.35% | 9 | $3.5K |
| 21 | Boston Scientific Corp | BSX | 0.33% | 79 | $3.3K |
| 22 | Medtronic PLC | MDT | 0.30% | 34 | $3.0K |
| 23 | Illumina Inc | ILMN | 0.27% | 10 | $2.6K |
| 24 | Becton Dickinson & Co | BDX | 0.24% | 13 | $2.4K |
| 25 | Moderna Inc | MRNA | 0.24% | 12 | $2.4K |
| 26 | IQVIA Holdings Inc | IQV | 0.23% | 9 | $2.3K |
| 27 | Medline Inc | MDLN | 0.23% | 65 | $2.3K |
| 28 | Cencora Inc | COR | 0.23% | 7 | $2.2K |
| 29 | UnitedHealth Group Inc | UNH | 0.22% | 6 | $2.2K |
| 30 | HCA Healthcare Inc | HCA | 0.22% | 5 | $2.2K |
| 31 | Waters Corp | WAT | 0.22% | 5 | $2.1K |
| 32 | Dexcom Inc | DXCM | 0.21% | 25 | $2.1K |
| 33 | Revolution Medicines Inc | RVMD | 0.21% | 11 | $2.1K |
| 34 | Humana Inc | HUM | 0.19% | 5 | $1.9K |
| 35 | Cash & Other | — | 0.19% | 1.90K | $1.9K |
| 36 | ResMed Inc | RMD | 0.18% | 8 | $1.8K |
| 37 | Edwards Lifesciences Corp | EW | 0.18% | 21 | $1.8K |
| 38 | CVS Health Corp | CVS | 0.18% | 20 | $1.8K |
| 39 | ELEVANCE HEALTH INC | ELV | 0.16% | 4 | $1.6K |
| 40 | Alnylam Pharmaceuticals Inc | ALNY | 0.16% | 7 | $1.6K |
| 41 | Centene Corp | CNC | 0.16% | 24 | $1.5K |
| 42 | Mettler-Toledo International Inc | MTD | 0.15% | 1 | $1.5K |
| 43 | Veeva Systems Inc | VEEV | 0.14% | 5 | $1.4K |
| 44 | Guardant Health Inc | GH | 0.13% | 8 | $1.3K |
| 45 | U.S. Bank Money Market Deposit Account… | — | 0.13% | 1.28K | $1.3K |
| 46 | Labcorp Holdings Inc | LH | 0.13% | 4 | $1.3K |
| 47 | Quest Diagnostics Inc | DGX | 0.12% | 5 | $1.2K |
| 48 | Summit Therapeutics Inc | SMMT | 0.11% | 66 | $1.1K |
| 49 | Cigna Group/The | CI | 0.11% | 4 | $1.1K |
| 50 | STERIS PLC | STE | 0.11% | 5 | $1.1K |
| 51 | Agilent Technologies Inc | A | 0.10% | 6 | $1.0K |
| 52 | Vertex Pharmaceuticals Inc | VRTX | 0.10% | 2 | $1.0K |
| 53 | GE HealthCare Technologies Inc | GEHC | 0.10% | 15 | $963.30 |
| 54 | Revvity Inc | PKI | 0.09% | 6 | $912.96 |
| 55 | Charles River Laboratories International Inc | CRL | 0.09% | 3 | $894.00 |
| 56 | ZIMMER BIOMET HOLDINGS INC | ZBH | 0.08% | 9 | $799.92 |
| 57 | Regeneron Pharmaceuticals Inc | REGN | 0.07% | 1 | $739.57 |
| 58 | West Pharmaceutical Services Inc | WST | 0.07% | 2 | $726.54 |
| 59 | Neurocrine Biosciences Inc | NBIX | 0.07% | 5 | $706.25 |
| 60 | Align Technology Inc | ALGN | 0.07% | 5 | $705.15 |
| 61 | Globus Medical Inc | GMED | 0.07% | 9 | $659.97 |
| 62 | Biogen Inc | BIIB | 0.07% | 3 | $655.29 |
| 63 | Penumbra Inc | PEN | 0.06% | 2 | $635.04 |
| 64 | Solventum Corp | SOLV | 0.06% | 7 | $604.87 |
| 65 | Medpace Holdings Inc | MEDP | 0.06% | 1 | $602.70 |
| 66 | Molina Healthcare Inc | MOH | 0.06% | 3 | $587.28 |
| 67 | Bio-Techne Corp | TECH | 0.06% | 8 | $579.60 |
| 68 | Tempus AI Inc | TEM | 0.06% | 8 | $554.24 |
| 69 | Tenet Healthcare Corp | THC | 0.05% | 2 | $521.14 |
| 70 | Axsome Therapeutics Inc | AXSM | 0.05% | 3 | $510.24 |
| 71 | Exelixis Inc | EXEL | 0.05% | 8 | $472.16 |
| 72 | Cooper Cos Inc/The | COO | 0.04% | 8 | $434.40 |
| 73 | Bio-Rad Laboratories Inc | BIO | 0.04% | 1 | $360.40 |
| 74 | DAVITA INC | DVA | 0.04% | 2 | $354.04 |
| 75 | Incyte Corp | INCY | 0.03% | 3 | $338.25 |
| 76 | BrightSpring Health Services Inc | BTSG | 0.03% | 4 | $254.64 |
| 77 | ENCOMPASS HEALTH CORP | EHC | 0.02% | 2 | $245.08 |
| 78 | Royalty Pharma PLC | RPRX | 0.02% | 4 | $224.84 |
| 79 | Baxter International Inc | BAX | 0.02% | 9 | $215.10 |
| 80 | Insmed Inc | INSM | 0.02% | 2 | $200.96 |
| 81 | Universal Health Services Inc | UHS | 0.02% | 1 | $175.72 |
| 82 | Ensign Group Inc/The | ENSG | 0.02% | 1 | $171.49 |
| 83 | Corcept Therapeutics Inc | CORT | 0.01% | 1 | $118.54 |
| 84 | Viatris Inc | VTRS | 0.01% | 5 | $87.20 |
| 85 | Bridgebio Pharma Inc | BBIO | 0.01% | 1 | $65.04 |
| 86 | BioMarin Pharmaceutical Inc | BMRN | 0.01% | 1 | $54.89 |
| 87 | Elanco Animal Health Inc | ELAN | 0.00% | 1 | $22.54 |
| 88 | 4GLD US 11/19/26 C476.95 FLX | — | -0.01% | -5 | -$107.65 |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | — | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | — | Last payment | — |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
No distributions in our database for this fund; it may not pay them, or history has not loaded yet.
Risk Statistics
Liquidity
| Volume today | 30 | Average volume | 135 |
| AUM | $996.6K | Premium/Discount | -0.07% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $996.6K → $996.6K |
| 1 Month | $5.6K | +0.57% | $988.5K → $996.6K |
| 1 Week | -$18.0K | -1.79% | $1.0M → $996.6K |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for MHIG
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.